105 investors have funded 19 Cell Therapy companies head-officed in Cambridge, across 184 rounds (Sep 2005 – Jan 2025). They are ranked by how many Cambridge companies in this market they have actually backed.
"In Cambridge" describes the companies, not the investor: most of the money in any city comes from somewhere else, and the Where the money comes from section below shows exactly where it came from here.
Ranked by companies backed in this market and city, then by round count. "Led" counts rounds recorded with this investor as lead.
| # | Investor | Based in | Stages here | Companies | Rounds | Led | Latest | Portfolio total |
|---|---|---|---|---|---|---|---|---|
| 1 | Bristol-Myers Squibb | New York City, United States | Series BSeries ASeries C | 4 | 7 | 1 | Jan 2025 | 64 |
| 2 | Atlas Venture | Cambridge, United States | Series ASeries BSeries C | 3 | 9 | 2 | Jan 2025 | 302 |
| 3 | Third Rock Ventures | Boston, United States | Series ASeries B | 3 | 4 | 3 | Jun 2021 | 70 |
| 4 | RA Capital Management | Boston, United States | Series ASeries BSeries C | 2 | 6 | 1 | Jan 2025 | 317 |
| 5 | Arch Venture Partners | Chicago, United States | Series ASeries BSeries C | 2 | 5 | 1 | Jan 2025 | 236 |
| 6 | Flagship Pioneering | Cambridge, United States | Series BSeries CSeries A | 2 | 5 | 1 | Jun 2017 | 106 |
| 7 | MPM Capital | Boston | Series ASeries B | 2 | 4 | 2 | Feb 2019 | 127 |
| 8 | Google Ventures | Mountain View, United States | Series ASeries B | 2 | 3 | 2 | Dec 2017 | 736 |
| 9 | Casdin Capital | New York City, United States | Series BSeries CSeries A | 2 | 3 | 1 | Dec 2020 | 136 |
| 10 | Samsara BioCapital | Palo Alto, United States | Series ASeries BSeries C | 2 | 3 | — | Apr 2024 | 99 |
| 11 | T1D Fund | Boston, United States | Series ASeries B | 2 | 3 | 1 | Jun 2021 | 34 |
| 12 | Invus | New York City, United States | Series A | 2 | 2 | — | Jun 2021 | 174 |
| 13 | Cowen | New York City, United States | Series B | 2 | 2 | 1 | Sep 2021 | 69 |
| 14 | 6 Dimensions Capital | Pudong, China | Series B | 2 | 2 | 1 | Feb 2019 | 54 |
| 15 | Amgen | Thousand Oaks, United States | Series BSeries A | 2 | 2 | — | Feb 2022 | 53 |
| 16 | Acks | Series ASeries B | 2 | 2 | — | Mar 2018 | 39 | |
| 17 | Alta Partners | Jackson, United States | Series BSeries ASeries C | 1 | 4 | — | Jan 2025 | 118 |
| 18 | Longwood Fund | Boston, United States | Series BSeries ASeries C | 1 | 4 | — | Jan 2025 | 44 |
| 19 | Takeda | Tokyo, Japan | Series ASeries BSeries C | 1 | 4 | — | Jan 2025 | 48 |
| 20 | Polaris Partners | Boston, United States | Series CSeries B | 1 | 3 | 1 | Sep 2009 | 330 |
| 21 | Highland Capital Partners | Menlo Park, United States | Series CSeries B | 1 | 3 | 1 | Sep 2009 | 236 |
| 22 | Access Industries | New York City, United States | Series ASeries BSeries C | 1 | 3 | — | Apr 2018 | 57 |
| 23 | Sequoia Capital | Menlo Park, United States | SeedSeries A | 1 | 2 | 1 | Jan 2020 | 1,568 |
| 24 | Khosla Ventures | Menlo Park, United States | SeedSeries A | 1 | 2 | 1 | Jan 2022 | 680 |
| 25 | F-Prime Capital | Cambridge, United States | Series ASeries B | 1 | 2 | — | Feb 2019 | 306 |
| 26 | 8VC | Austin, United States | SeedSeries A | 1 | 2 | 1 | Jan 2022 | 324 |
| 27 | Hummingbird Ventures | London, United Kingdom | Series ASeed | 1 | 2 | 2 | Feb 2022 | 79 |
| 28 | Baidu Ventures | SeedSeries A | 1 | 2 | — | Jan 2020 | 100 | |
| 29 | Logos | San Francisco, United States | Series BSeries C | 1 | 2 | — | Apr 2024 | 99 |
| 30 | Citadel | Chicago, United States | Series BSeries C | 1 | 2 | — | Apr 2024 | 99 |
| 31 | Medtronic | Minneapolis, United States | Series ASeries B | 1 | 2 | — | Feb 2019 | 56 |
| 32 | Volcanics Venture | Shanghai, China | SeedSeries A | 1 | 2 | — | Jan 2020 | 58 |
| 33 | Deep Track Capital | Greenwich, United States | Series BSeries C | 1 | 2 | — | Apr 2024 | 55 |
| 34 | Engine | Cambridge, United States | SeedSeries A | 1 | 2 | 1 | Jan 2022 | 27 |
| 35 | Vertex Ventures HC | Palo Alto, United States | Series ASeries B | 1 | 2 | — | Sep 2021 | 24 |
| 36 | TCG Crossover | Palo Alto, United States | Series BSeries C | 1 | 2 | 1 | Apr 2024 | 33 |
| 37 | Partners Health Care Innovation | Cambridge, United States | Series ASeries B | 1 | 2 | — | May 2017 | 18 |
| 38 | Humboldt Fund | New York City, United States | SeedSeries A | 1 | 2 | 1 | Jan 2022 | 17 |
| 39 | Nest Bio Ventures | Cambridge, United States | SeedSeries A | 1 | 2 | — | Jan 2020 | 10 |
| 40 | MDB Capital Holdings | Dallas, United States | SeedSeries A | 1 | 2 | — | Dec 2016 | 1 |
| 41 | Andreessen Horowitz | New York City, United States | Series A | 1 | 1 | — | Sep 2024 | 1,117 |
| 42 | Lightspeed Venture Partners | Menlo Park, United States | Series A | 1 | 1 | — | Jun 2021 | 860 |
| 43 | Felicis Ventures | Menlo Park, United States | Series A | 1 | 1 | — | Jan 2022 | 375 |
| 44 | Matrix | San Francisco, United States | Series B | 1 | 1 | — | Sep 2021 | 320 |
| 45 | Eight Roads Ventures | London, United Kingdom | Series B | 1 | 1 | 1 | Feb 2019 | 333 |
| 46 | Hillhouse | New York City, United States | Series B | 1 | 1 | — | Mar 2018 | 341 |
| 47 | Novo Holdings | Hellerup, Denmark | Series C | 1 | 1 | — | Apr 2024 | 286 |
| 48 | LocalGlobe | London, United Kingdom | Seed | 1 | 1 | 1 | Oct 2024 | 208 |
| 49 | Alexandria | Pasadena, United States | Series A | 1 | 1 | — | Dec 2020 | 231 |
| 50 | CDH | Kowloon, China | Series B | 1 | 1 | 1 | Sep 2021 | 224 |
| 51 | Wellington | Boston, United States | Series C | 1 | 1 | 1 | Apr 2024 | 221 |
| 52 | Novartis Venture Fund | Basel, Switzerland | Series A | 1 | 1 | — | Dec 2020 | 139 |
| 53 | Mubadala | Abu Dhabi, United Arab Emirates | Series A | 1 | 1 | — | Sep 2024 | 167 |
| 54 | Janus Henderson Investors | London, United Kingdom | Series C | 1 | 1 | — | Apr 2024 | 164 |
| 55 | Foresite Capital | New York City, United States | Series C | 1 | 1 | — | Apr 2024 | 116 |
| 56 | Redmile Group | San Francisco, United States | Series B | 1 | 1 | — | Mar 2018 | 113 |
| 57 | Yuanhe Holdings | Suzhou, China | Series A | 1 | 1 | 1 | Jan 2020 | 130 |
| 58 | Cathay Capital | Paris, France | Series B | 1 | 1 | — | Mar 2018 | 127 |
| 59 | Emerson Collective | Palo Alto, United States | Series A | 1 | 1 | — | Nov 2021 | 108 |
| 60 | Lilly | Indianapolis, United States | Series A | 1 | 1 | — | Dec 2020 | 110 |
| 61 | Novartis | Basel, Switzerland | Series B | 1 | 1 | — | Feb 2019 | 89 |
| 62 | RTW Investments | New York City, United States | Series C | 1 | 1 | — | Apr 2024 | 80 |
| 63 | EcoR1 | San Francisco, United States | Series C | 1 | 1 | — | Apr 2018 | 76 |
| 64 | Cormorant Asset Management | Boston, United States | Series A | 1 | 1 | 1 | Sep 2024 | 77 |
| 65 | Catalio Capital Management | New York City, United States | Series A | 1 | 1 | — | Dec 2020 | 70 |
| 66 | Nextech Invest | Zurich, Switzerland | Series C | 1 | 1 | 1 | Jan 2025 | 57 |
| 67 | Sky9 Capital | Shanghai, China | Series B | 1 | 1 | 1 | Sep 2021 | 68 |
| 68 | BlueYard | Berlin, Germany | Seed | 1 | 1 | — | Oct 2024 | 51 |
| 69 | ArrowMark Partners | Denver, United States | Series B | 1 | 1 | — | Mar 2018 | 55 |
| 70 | F2 Capital | Tel Aviv, Israel | Series B | 1 | 1 | — | Mar 2018 | 37 |
| 71 | AbbVie | Chicago, United States | Series A | 1 | 1 | — | Dec 2020 | 47 |
| 72 | Leaps by Bayer | Leverkusen, Germany | Series A | 1 | 1 | 1 | Jan 2022 | 45 |
| 73 | Takeda Ventures | Palo Alto, United States | Series A | 1 | 1 | — | Dec 2017 | 44 |
| 74 | Mirae Asset Venture | Seoul, South Korea | Series B | 1 | 1 | — | Mar 2018 | 50 |
| 75 | Soleus Capital | Greenwich, United States | Series B | 1 | 1 | — | Sep 2021 | 44 |
| 76 | Amgen Business Development | Thousand Oaks, United States | Series A | 1 | 1 | — | Dec 2017 | 37 |
| 77 | Apple Tree Partners | New York City, United States | Series C | 1 | 1 | 1 | Nov 2021 | 31 |
| 78 | Civilization Ventures | San Francisco, United States | Series A | 1 | 1 | — | Feb 2022 | 33 |
| 79 | Syncona | London, United Kingdom | Series A | 1 | 1 | 1 | Nov 2021 | 23 |
| 80 | LifeSci Venture Partners | New York City, United States | Series A | 1 | 1 | — | Nov 2021 | 32 |
| 81 | Sinopharm Capital | Huangpu, China | Series B | 1 | 1 | — | Feb 2019 | 34 |
| 82 | Wu Capital | San Mateo, United States | Series B | 1 | 1 | — | Feb 2019 | 24 |
| 83 | Pivotal bioVenture Partners | Series B | 1 | 1 | — | Sep 2021 | 23 | |
| 84 | Eventide Funds | Series C | 1 | 1 | — | Apr 2018 | 25 | |
| 85 | SVB Securities | Boston, United States | Series B | 1 | 1 | — | Mar 2018 | 17 |
| 86 | ORI Capital | Hong Kong, China | Series B | 1 | 1 | — | Feb 2019 | 9 |
| 87 | F2 Ventures | London, United Kingdom | Series A | 1 | 1 | 1 | Dec 2016 | 8 |
| 88 | Onsight Ventures | Innsbruck, Austria | Seed | 1 | 1 | — | Oct 2024 | 10 |
| 89 | Haitong International Securities Group | Hong Kong, China | Series B | 1 | 1 | — | Mar 2018 | 10 |
| 90 | BioScience Managers | Melbourne, Australia | Post-IPO | 1 | 1 | — | Oct 2015 | 8 |
| 91 | HBM Genomics | Palo Alto, United States | Series A | 1 | 1 | — | Feb 2022 | 5 |
| 92 | Sirona Capital | Perth, Australia | Series B | 1 | 1 | — | Mar 2018 | 6 |
| 93 | ShangPharma Innovation | San Francisco, United States | Series A | 1 | 1 | — | Dec 2017 | 5 |
| 94 | Blue Owl Healthcare Opportunities | Series C | 1 | 1 | — | Apr 2024 | 5 | |
| 95 | Syno Capital | New York City, United States | Series B | 1 | 1 | — | Mar 2018 | 3 |
| 96 | Paradigm BioCapital | New York City, United States | Series C | 1 | 1 | — | Apr 2024 | 5 |
| 97 | Oceania Capital Partners | Belrose, Australia | Post-IPO | 1 | 1 | — | Oct 2015 | 4 |
| 98 | Shandong Lucion Investment Holdings Group | Jinan, China | Series B | 1 | 1 | — | Mar 2018 | 4 |
| 99 | Curative Ventures | Dallas, United States | Series B | 1 | 1 | 1 | Mar 2018 | 3 |
| 100 | Hunter Hall | Sydney, Australia | Post-IPO | 1 | 1 | — | Oct 2015 | 3 |
Showing the top 100 of 105. Search the full investor set →
Head office of the investors on this page.
Rounds by stage — where in a company's life this money arrives.
Total disclosed size of each round, not one investor's share.
How active this market has been.
Cell Therapy companies head-officed in Cambridge that took money from these investors.
| Company | Backers | Rounds | Disclosed | Latest round |
|---|---|---|---|---|
| Obsidian Therapeutics obsidiantx.com |
25 | 35 | $4.2B | Series C Apr 2024 |
| TCR2 Therapeutics tcr2.com |
16 | 17 | $2B | Series B Mar 2018 |
| Semma Therapeutics semma-tx.com |
12 | 17 | $1.5B | Series B Feb 2019 |
| Magenta Therapeutics magentatx.com |
9 | 16 | $802.5M | Series C Apr 2018 |
| Be Bio be.bio |
8 | 27 | $2.5B | Series C Jan 2025 |
| Faze Medicines fazemed.com |
8 | 8 | $648M | Series A Dec 2020 |
| RootPath Genomics rootpath.com |
8 | 12 | $233M | Series B Sep 2021 |
| Abata abatatx.com |
7 | 7 | $570M | Series A Aug 2024 |
| Cellino cellinobio.com |
6 | 10 | $544M | Series A Jan 2022 |
| Avita Medical avitamedical.com |
5 | 5 | $38M | Post-IPO Dec 2018 |
| Clade cladetx.com |
4 | 4 | $348M | Series A Nov 2021 |
| Kernal Biologics kernalbio.com |
4 | 5 | $110M | Series A Feb 2022 |
| GCTx gc-tx.com |
3 | 3 | $195M | Series A Sep 2024 |
| Pervasis Therapeutics pervasistx.com |
3 | 9 | $95.3M | Series C Sep 2009 |
| Clock.bio clock.bio |
3 | 3 | $15.9M | Seed Oct 2024 |
| Rubius Therapeutics rubiustx.com |
1 | 2 | $145M | Series B Jun 2017 |
| Marengo marengotx.com |
1 | 1 | $80M | Series C Nov 2021 |
| Vericel Corporation vcel.com |
1 | 1 | $40M | PE Mar 2012 |
| Cue Biopharma cuebiopharma.com |
1 | 2 | $26.4M | Series A Dec 2016 |
| Date | Investor | Company | Stage | Round size |
|---|---|---|---|---|
| Jan 2025 | Atlas Venture | Be Bio | Series C | $92M |
| Jan 2025 | Arch Venture Partners | Be Bio | Series C | $92M |
| Jan 2025 | Alta Partners | Be Bio | Series C | $92M |
| Jan 2025 | RA Capital Management | Be Bio | Series C | $92M |
| Jan 2025 | Takeda | Be Bio | Series C | $92M |
| Jan 2025 | Nextech InvestLED | Be Bio | Series C | $92M |
| Jan 2025 | Bristol-Myers Squibb | Be Bio | Series C | $92M |
| Jan 2025 | Longwood Fund | Be Bio | Series C | $92M |
| Oct 2024 | Alta Partners | Be Bio | Series B | $82M |
| Oct 2024 | Longwood Fund | Be Bio | Series B | $82M |
| Oct 2024 | Atlas Venture | Be Bio | Series B | $82M |
| Oct 2024 | Arch Venture Partners | Be Bio | Series B | $82M |
| Oct 2024 | RA Capital Management | Be Bio | Series B | $82M |
| Oct 2024 | Takeda | Be Bio | Series B | $82M |
| Oct 2024 | Bristol-Myers Squibb | Be Bio | Series B | $82M |
| Oct 2024 | BlueYard | Clock.bio | Seed | $5.3M |
| Oct 2024 | LocalGlobeLED | Clock.bio | Seed | $5.3M |
| Oct 2024 | Onsight Ventures | Clock.bio | Seed | $5.3M |
| Sep 2024 | a16z | GCTx | Series A | $65M |
| Sep 2024 | Mubadala | GCTx | Series A | $65M |
Cell Therapy investors in other cities
Other markets in Cambridge